At a glance
ClinicalIndex Comparison RecordPhase 2Active· 55 enrolled
Drug / intervention
Duvelisib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome
In Brief
A Phase 2 clinical trial evaluating Duvelisib and Venetoclax for Chronic Lymphocytic Leukemia and Richter Syndrome. Active but no longer recruiting, targeting 55 participants across 7 sites.
Detailed Summary
This research study is assessing a new drug, duvelisib, in combination with a drug that is already FDA approved, venetoclax, as a possible treatment for participants with CLL or those with Richter's Syndrome
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia, Richter Syndrome
CountriesUnited States
CollaboratorsSecura Bio, Inc.
Timeline
Phase 2ActiveOverdue
20192020202120222023202420252026
First PostedMay 2018
Enrollment StartJul 2018
Primary CompletionDec 2024
Study CompletionJul 2026
TodayJul 2026
First PostedMay 23, 2018
Enrollment StartJul 12, 2018
Primary CompletionDec 1, 2024
Study CompletionJul 1, 2026
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 8.1 years ago
Interventions
Duvelisibdrug
This drug is designed to stop cancer growth by blocking a protein called phosphatidylinositide 3-kinase (PI3K), which is important for the survival of CLL cells.
Venetoclaxdrug
Venetoclax targets a protein called BCL-2, which helps cancer cells survive.